Diagnosis and management of acute myeloid leukemia with mutated CEBPA using CEBPA-Trass, a targeted sequencing approach
Acute myeloid leukemia (AML) with mutated CEBPA (CEBPA-AML) was first recognized as a distinct subtype associated with favorable prognosis in 2002, and its diagnostic criteria and clinical management have been refined over time. However, several challenges remain, including the lack of accurate mutation-based methods for measurable residual disease (MRD) detection. Here, we developed a targeted next-generation sequencing approach for the CEBPA gene, which uses adapter-free PCR amplification of hotspot regions followed by paired-end sequencing to improve analytical performance (termed CEBPA-Trass), and evaluated its clinical performance in samples from the WT1-AM-04 study. CEBPA-Trass successfully detected a cryptic long insertion missed by conventional short-read sequencing. Analytical validation showed higher background for missense variants, whereas insertions or deletions involving three or more base pairs were rarely detected in negative controls and typically below 10⁻⁴, indicating high analytical specificity. Dilution experiments further showed linear detection of insertions or deletions involving three or more base pairs with a limit of detection of 10⁻⁴ -10⁻⁵, comparable to the sensitivity of real-time PCR-based MRD assays, and aligned with the in-frame mutation patterns currently associated with favorable-risk CEBPA-AML. Clinically, CEBPA-Trass-based MRD assessment significantly stratified relapse risk after both first and last consolidation therapy. Specifically, the assessment after last consolidation showed that more than 80% of MRD-positive patients relapsed, whereas more than 80% of MRD-negative patients remained in remission for over two years. These findings suggest that CEBPA-Trass enables accurate mutation-based MRD monitoring and may improve both the diagnosis and risk stratification of patients with CEBPA-AML.
Authors
- Hitoshi Hanamoto (ORCID: https://orcid.org/0009-0003-3291-5280)
- Osamu Imataki (ORCID: https://orcid.org/0000-0001-5332-1316)
- Tatsuya Imi (ORCID: https://orcid.org/0000-0002-7674-7368)
- Daisuke Motooka (ORCID: https://orcid.org/0000-0002-4616-9608)
- Norimitsu Kadowaki (ORCID: https://orcid.org/0000-0002-6473-800X)
- Akihiro Tsuboi (ORCID: https://orcid.org/0000-0003-3182-2456)
- Yuta Katayama (ORCID: https://orcid.org/0000-0001-5054-9104)
- Hideaki� Yoshimura (ORCID: https://orcid.org/0000-0002-7287-7712)
- Kensuke Usuki (ORCID: https://orcid.org/0000-0002-1216-4470)
- Haruo Sugiyama (ORCID: https://orcid.org/0000-0002-0844-2175)
- Shigeki Ito (ORCID: https://orcid.org/0000-0002-3899-6603)
- Noboru Asada (ORCID: https://orcid.org/0000-0001-7322-5460)
- Atsushi Kumanogoh (ORCID: https://orcid.org/0000-0003-4749-7117)
- Fumihiro Fujiki (ORCID: https://orcid.org/0000-0002-2433-510X)
- Junya Kuroda (ORCID: https://orcid.org/0000-0001-6130-1550)
- Yasuhiko Shibasaki (ORCID: https://orcid.org/0000-0002-3865-4056)
- Yusuke Oji (ORCID: https://orcid.org/0000-0002-2935-1184)
- Hiroki Hosoi (ORCID: https://orcid.org/0000-0002-8682-7476)
- Jun Nakata (ORCID: https://orcid.org/0000-0002-7494-1204)
- Shuichi Ota (ORCID: https://orcid.org/0000-0002-3631-244X)
- Takayuki Ikezoe (ORCID: https://orcid.org/0000-0002-7858-278X)
- Ryota Imanaka
- Masahiko Fukatsu (ORCID: https://orcid.org/0000-0002-7957-0000)
- Atsushi� Satake (ORCID: https://orcid.org/0000-0002-6007-6264)
- Masayoshi Masuko (ORCID: https://orcid.org/0000-0002-3760-3089)
- Taku Tsukamoto (ORCID: https://orcid.org/0000-0002-6803-5491)
- Makoto Onizuka (ORCID: https://orcid.org/0000-0003-3864-0823)
- Tatsuo Oyake (ORCID: https://orcid.org/0000-0002-8457-2211)
- Soyoko Morimoto (ORCID: https://orcid.org/0000-0002-4939-0455)
- Yoshiki Nakae
- Kazunori Murai (ORCID: https://orcid.org/0000-0002-7353-3495)
- Yuki Takada (ORCID: https://orcid.org/0000-0002-8359-5024)
- Hiroko Nakajima (ORCID: https://orcid.org/0000-0003-1686-8819)
- Takeshi Maeda (ORCID: https://orcid.org/0009-0009-4059-1777)
- Takashi Sonoki (ORCID: https://orcid.org/0000-0002-0211-3311)
- Yukio Oka (ORCID: https://orcid.org/0009-0005-9171-6585)
- Manabu Kawakami
- Hiroyuki Yamano
Institutions
- Kanazawa University (JP)
- Osaka Gakuin University (JP)
- Kansai Medical University (JP)
- Fukushima Medical University (JP)
- Tokai University (JP)
- Okayama University (JP)
- Iwate Medical University (JP)
- Wakayama Medical University (JP)
- Kagawa University (JP)
- Osaka City University (JP)
- Kyoto Prefectural University of Medicine (JP)
- Kurashiki Central Hospital (JP)
- Iwate Prefectural Central Hospital (JP)
- Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital (JP)
- Sapporo Hokuyu Hospital (JP)
- Nippon Life Hospital (JP)
- Teikyo University Hospital, Mizonokuchi (JP)
- Kindai University Nara Hospital (JP)
- Research Institute for Microbial Diseases, The University of Osaka (JP)
- Niigata University (JP)
- Teikyo University (JP)
- Kindai University (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- Blood Advances
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1182/bloodadvances.2026021717
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00